Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanoliposomal amphotericin B for treatment-resistant dermatophytosis
IRCT20240711062393N2Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in dermatophytosis comparing Nanoliposomal amphotericin B, Nanoliposomal amphotericin B + itraconazole and Itraconazole control (3 arms). Primary endpoints: Complete recovery of clinical symptoms and Negative mycological criteria. Started Jul 2025; status: completed.
02
Drugs
amphotericin bitraconazole
03
Conditions
dermatophytosis
Beyond the preview
Go deeper on IRCT20240711062393N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240711062393N2.